Histone acetyltransferase p300 (EP300) inhibitors have been reported in a Kronos Bio Inc. patent and are described as potentially useful for the treatment of cancer and inflammatory disorders.
Hitgen Ltd. has prepared and tested interleukin-17 receptor A (IL17RA; CD217) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, asthma, multiple sclerosis, psoriasis, rheumatoid arthritis and inflammatory disorders.
Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Work at The Cleveland Clinic Foundation has led to the identification of new 3β-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 (3β-HSD1, HSD3B1) inhibitors reported to be useful for the treatment of cancer.
A Merck Sharp & Dohme LLC patent details new GTPase KRAS and its G12C, G12D, G12V and/or G13D mutant inhibitors reported to be useful for the treatment of cancer.
The Research Foundation of State University of New York and the U.S. Department of Health and Human Services have jointly developed prazole-based compounds acting as H+/K+-ATPase inhibitors and thus reported to be useful for the treatment of viral infections.
Arrepath Inc. has patented new UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.
Planting seed money and “wishing” is not enough to claim “irreparable harm” to secure a preliminary injunction or to establish the standing required to appeal a patent board decision, the U.S. Court of Appeals for the Federal Circuit ruled May 7 in two decisions involving Incyte Corp. and Sun Pharmaceutical Industries Ltd.
RSS
